bullish
Celltrion (068270 KS): 2Q24 Result- Biosimilar Sales Roar; Operating Profit Recovers Sequentially
198 Views07 Aug 2024 20:14
Celltrion posted record high quarterly sales for the second consecutive quarter, with balanced growth in core and new biosimilar products. Operating profit improved by a massive 371% sequentially.
What is covered in the Full Insight:
- Q2 24 Financial Performance
- Biosimilars on High Trajectory
- Operating Profit Improvement Outlook
- Approval of New Biosimilar Products
- Conclusion and Outlook
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Celltrion (068270 KS): 2Q24 Result- Biosimilar Sales Roar; Operating Profit Recovers Sequentially07 Aug 2024
- Celltrion (068270 KS): 1Q24 Result- Sales Hit Quarterly High; Profit Sinks on Merger Effect10 May 2024
- Celltrion (068270 KS): Solid Performance in Core Business in 2023; Eyes 60% Sales Growth in 202402 Mar 2024
x